Patients need less of your drug? Time to triple the price
#3 Shkreli Award Winner, 2018 A group of oncologists at the Value in Cancer Care Consortium, a non-profit research organization, found early clinical evidence that the blood cancer drug Imbruvica may be just as effective at a lower dose after initial treatment. A few months later, Janssen and Pharmalytics, the companies that sell Imbruvica, announced that they would now sell the pill in four different strengths, with each pill at triple the original price.
SOURCE: Carolyn Y. Johnson, The Washington Post